stoxline Quote Chart Rank Option Currency Glossary
  
Profound Medical Corp. (PROF)
8.53  0.41 (5.05%)    03-28 16:00
Open: 8.2
High: 8.53
Volume: 17,026
  
Pre. Close: 8.12
Low: 8.2
Market Cap: 208(M)
Technical analysis
2024-03-28 4:53:42 PM
Short term     
Mid term     
Targets 6-month :  10.99 1-year :  12.84
Resists First :  9.41 Second :  10.99
Pivot price 8.27
Supports First :  8.17 Second :  7.4
MAs MA(5) :  8.26 MA(20) :  8.45
MA(100) :  8.88 MA(250) :  10.15
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  53.4 D(3) :  46
RSI RSI(14): 52.5
52-week High :  15.48 Low :  7.11
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ PROF ] has closed below upper band by 11.0%. Bollinger Bands are 65.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 8.54 - 8.58 8.58 - 8.61
Low: 8.12 - 8.15 8.15 - 8.19
Close: 8.47 - 8.53 8.53 - 8.6
Company Description

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain relief associated with metastases in bone, as well as non-invasive treatment of uterine fibroids. Profound Medical Corp. is headquartered in Mississauga, Canada.

Headline News

Fri, 22 Mar 2024
Profound Medical (NASDAQ:PROF) Stock Price Down 0.1% - MarketBeat

Fri, 22 Mar 2024
Profound Medical (NASDAQ:PROF) Shares Down 0.1% - Defense World

Fri, 08 Mar 2024
Profound Medical Corp. (NASDAQ:PROF) Q4 2023 Earnings Call Transcript - Yahoo Finance

Thu, 07 Mar 2024
Profound Medical Announces Fourth Quarter and Full Year 2023 Financial Results - Morningstar

Thu, 07 Mar 2024
Profound Medical Reports Revenue Growth and Expansions - TipRanks.com - TipRanks

Thu, 07 Mar 2024
Profound Medical Corp. (PROF) Q4 2023 Earnings Call Transcript - Seeking Alpha

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Medical - Devices
Shares Out 24 (M)
Shares Float 22 (M)
Held by Insiders 8.6 (%)
Held by Institutions 41 (%)
Shares Short 328 (K)
Shares Short P.Month 350 (K)
Stock Financials
EPS -1.36
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.46
Profit Margin 0 %
Operating Margin -437.2 %
Return on Assets (ttm) -33.1 %
Return on Equity (ttm) -68.7 %
Qtrly Rev. Growth 59.7 %
Gross Profit (p.s.) 0
Sales Per Share 0.29
EBITDA (p.s.) -1.15
Qtrly Earnings Growth 0 %
Operating Cash Flow -22 (M)
Levered Free Cash Flow -13 (M)
Stock Valuations
PE Ratio -6.32
PEG Ratio 0
Price to Book value 5.84
Price to Sales 28.94
Price to Cash Flow -9.35
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android